Why Is Moderna Stock Trading Higher Today?
Portfolio Pulse from Vandana Singh
Moderna Inc plans to launch up to 15 new products and advance up to 50 mRNA medicines into clinical trials over the next five years. The company expects sales of its respiratory vaccines to range between $8 billion and $15 billion in 2027, with another $10 billion to $15 billion from annual sales of cancer, rare disease, and latent disease medicines it will launch by 2028. Moderna also plans to invest $25 billion in Research and development from 2024 through 2028. In partnership with Merck & Co Inc, Moderna plans to begin a second Phase 3 trial of mRNA-4157, its individualized neoantigen therapy, in combination with Keytruda, for non-small cell lung cancer later this year.
September 13, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Merck & Co Inc is partnering with Moderna for a second Phase 3 trial of mRNA-4157, Moderna's individualized neoantigen therapy, for non-small cell lung cancer.
Merck's partnership with Moderna for a second Phase 3 trial of mRNA-4157 could potentially lead to a successful treatment for non-small cell lung cancer, which could positively impact Merck's stock.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Moderna's announcement of new product launches and clinical trials, along with expected significant sales, has led to a rise in its stock price.
The announcement of new product launches and clinical trials, along with expected significant sales, has led to increased investor confidence in Moderna, resulting in a rise in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100